A Biotech Bloom in July

The best performing sector in the past month has been biotech. With investors flocking to safety due to recent financial turmoil and the sharp correction in energy, funds and investors have been warming up to biotech.

The biotech sector is not without its large risks though and investing here requires more homework and experience than most sectors. The biotech landscape is full of landmines especially with unproven companies with their yet to be proven drugs. The recent backlash the FDA has received due to major flaws in its Vioxx approval and other well publicized failed post approval drugs has made future FDA committees and agency approvals much more stringent in safety profiling and thorough in analysis of drug data.